THERAPEUTIC IMPLANT

• US 20080020011A1
• Filed: 05/17/2007
• Published: 01/24/2008
• Est. Priority Date: 11/19/2004
• Status: Abandoned Application

• Current Assignee: Dina Katsir, Zvi Finkelstein
• Original Assignee: Dina Katsir, Zvi Finkelstein
• Inventors: Finkelstein, Zvi, Katsir, Dina
• Application Number:
  US11/749,848
• Publication Number:
  US 20080020011A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61F 2210/0095 radioactive
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/256 Antibodies, e.g. immunoglobulins, vaccines
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00

Abstract

The invention relates an implant, which comprises a biologically compatible substrate, to which at least one moiety is bound by a ligand, the moiety being one which specifically binds to and selectively immobilizes, at least one known target present in body fluid. The moiety traps the target and thus enables undesired materials present in a body fluid to be destroyed locally in situ, or alternatively to be removed and destroyed ex vivo. A method for selectively removing from a mammalian body fluid in situ, at least one known target, also forms part of the invention.

Claims

1. An implant, adapted for insertion in a mammalian body cavity, for use in selectively removing from a body fluid and immobilizing on said implant, at least one known target selected from pathogenic factors, antigens and antigenic determinants, including cells and cell fragments which are at least in part cancerous or pathogenically infected, wherein said implant comprises a surface layer including at least one moiety selected from antibodies and fragments thereof, which specifically bind to said at least one known target, and wherein said implant comprises a biologically compatible substrate, to which said at least one moiety is bound by a ligand in said surface layer.

2. Implant according to claim 1, wherein said moiety is selected from

monoclonal antibodies, polyclonal antibodies, synthetic antibodies, antigenic affinity synthetic fragments, antibody fragments retaining their antigenic affinity, Fv antibody fragments, radio labelled antibodies and biotinylated antibodies.

3. Implant according to claim 1, which is further characterized by at least one of the following features:

(a) said at least one target is selected from entities comprising antigens and antigenic determinants, and said at least one moiety is selected from monoclonal antibodies which are specific for said at least one target;

(b) it includes a device for connection to a catheter;

(c) it includes, and is adapted for slow release of, at least one pharmacologically active compound selected from the group consisting of antibacterial drugs, anti-fungal drugs, anti-neoplastic drugs, anti-thrombotic drugs, anti-toxin drugs and antiviral drugs.

4. Implant according to claim 3, wherein said substrate is selected from natural and synthetic polymers, ceramics, glass, metals, metal oxides and fabrics.

5. Implant according to claim 4, which is further characterized by at least one of the following features:

said ligand comprises at least one substance selected from avidin, biotin, streptavidin, and their analogues;

said monoclonal antibodies bind specifically to B- or T-cell antigenic determinants.

23. An essentially multi-part intra-luminal device, adapted for insertion into and retrieval from a mammalian body cavity, which comprises a combination of at least two concentric tubes separated by spacers, wherein at least one of said tubes is an implant as defined in claim 1, and at least one other of said tubes carries a therapeutically active substance selected from chemotherapeutic compounds and a sealed radiation source.

24. A device according to claim 23, wherein in said implant, said moiety is selected from monoclonal antibodies, polyclonal antibodies, synthetic antibodies, antigenic affinity synthetic fragments, antibody fragments retaining their antigenic affinity, Fv antibody fragments, radio labelled antibodies and biotinylated antibodies.

28. A device according to claim 23, wherein said implant is further characterized by at least one of the following features:

(a) said at least one target is selected from entities comprising antigens and antigenic determinants, and said at least one moiety is selected from monoclonal antibodies which are specific for said at least one target;

(b) it includes a device for connection to a catheter;

(c) it includes, and is adapted for slow release of, at least one pharmacologically active compound selected from the group consisting of antibacterial drugs, anti-fungal drugs, anti-neoplastic drugs, anti-thrombotic drugs, anti-toxin drugs and antiviral drug;

.

(d) said substrate is selected from natural and synthetic polymers, ceramics, glass, metals, metal oxides and fabrics;

(e) said ligand comprises at least one substance selected from avidin, biotin, streptavidin, and their analogues;

(f) said monoclonal antibodies bind specifically to B- or T-cell antigenic determinants.

6. A method for selectively removing from a mammalian body fluid in situ, at least one known target, which comprises the following steps (A) and either (B) or (C), namely:

(A) exposing to said body fluid in a cavity of said mammalian body, an implant inserted in said cavity, wherein said implant comprises a surface layer including at least one moiety which specifically binds to and thus immobilizes said at least one known target, and wherein said implant comprises a biologically compatible substrate, to which said at least one moiety is bound by a ligand in said surface layer; and

, after a predetermined time interval,

either (B) removing from said mammalian body cavity, said implant including said at least one target which is bound to said at least one moiety, and in an optional further step, destroying ex-vivo said at least one target bound to said at least one moiety;

or (C) destroying in situ said at least one target bound to said at least one moiety.

7. Method according to claim 6, wherein said moiety is selected from proteins, polypeptide or fragments thereof, antibodies or fragments thereof, carbohydrates (including polysaccharides), hormones, antioxidants, glycoproteins, lipoproteins, lipids, fat soluble vitamins, bile acids, reactive dyes, allantoin, uric acid, polymyxin, nucleic acid molecules (DNA, RNA, single stranded, double stranded, triple stranded or combinations thereof), or combinations thereof.

8. Method according to claim 6, wherein said moiety is selected from monoclonal antibodies, polyclonal antibodies, synthetic antibodies, antigenic affinity synthetic fragments, antibody fragments retaining their antigenic affinity, Fv antibody fragments, radio labelled antibodies and biotinylated antibodies.

9. Method according to claim 6, which is further characterized by at least one of the following features:

(a) said at least one target is selected from entities comprising antigens and antigenic determinants, and said at least one moiety is selected from monoclonal antibodies which are specific for said at least one target;

(b) said implant is connectable to a catheter;

(c) said implant includes, and is adapted for slow release of, at least one pharmacologically active compound selected from the group consisting of antibacterial drugs, anti-fungal drugs, anti-neoplastic drugs, anti-thrombotic drugs, anti-toxin drugs and antiviral drugs;

(d) said body cavity is a blood vessel and said body fluid is blood;

(e) said at least one target is selected from a population of cells and cell fragments, which is at least in part cancerous or pathogenically infected;

(f) said optional further step and said step (C) are carried out by locally applying to said at least one target which is bound to said at least one moiety, at least one of the following, namely, radiation, heat (hyperthermia), sonication, immunotherapy, radioimmunotherapy, genetic therapy or controlled drug release;

(g) the specific monoclonal antibodies in the surface layer are renewed and(or) supplemented by direct administration to the mammalian body of monoclonal antibodies adapted for specific binding to the implant as well as to said target.

10. Method according to claim 9, which is further characterized by at least one of the following features:

(i) said substrate is selected from natural and synthetic polymers, ceramics, glass, metals, metal oxides and fabrics;

(ii) said at least one target is selected from cancer-affected cells such as mature B-cells and T-cells.

(iii) said directly administered monoclonal antibodies comprise a bound ligand.

11. Method according to claim 10, which is further characterized by at least one of the following features:

said ligand comprises at least one substance selected from avidin, biotin, streptavidin, and their analogues;

said monoclonal antibodies bind specifically to B- or T-cell antigenic determinants.

12. An implant for use in selectively removing from a mammalian body fluid and immobilizing on said implant, at least one known target selected from pathogenic factors, antigens and antigenic determinants, including cells and cell fragments which are at least in part cancerous or pathogenically infected, wherein said implant comprises a surface layer including at least one moiety selected from antibodies and fragments thereof, which specifically bind to said at least one known target, and comprises also a biologically compatible substrate, to which said at least one moiety is bound by a ligand in said surface layer, said implant being either adapted for suspension within the internal hollow space of an intra-luminal stent, or being suspended within the internal hollow space of an intra-luminal stent prior to insertion of the stent together with its suspended implant in the mammalian body.

13. Implant according to claim 12, wherein said moiety is selected from monoclonal antibodies, polyclonal antibodies, synthetic antibodies, antigenic affinity synthetic fragments, antibody fragments retaining their antigenic affinity, Fv antibody fragments, radio labelled antibodies and biotinylated antibodies.

14. Implant according to claim 12, which is further characterized by at least one of the following features:

(a) said at least one target is selected from entities comprising antigens and antigenic determinants, and said at least one moiety is selected from monoclonal antibodies which are specific for said at least one target;

(b) it includes a device for connection to a catheter;

(c) it includes, and is adapted for slow release of, at least one pharmacologically active compound selected from the group consisting of antibacterial drugs, antifungal drugs, anti-neoplastic drugs, anti-thrombotic drugs, anti-toxin drugs and antiviral drugs.

15. Implant according to claim 14, wherein said substrate is selected from natural and synthetic polymers, ceramics, glass, metals, metal oxides and fabrics.

16. Implant according to claim 15, which is further characterized by at least one of the following features:

said ligand comprises at least one substance selected from avidin, biotin, streptavidin, and their analogues;

said monoclonal antibodies bind specifically to B- or T-cell antigenic determinants.

17. A method for selectively removing from a mammalian body fluid in situ, at least one known target, which comprises the following steps (A) and either (B) or (C), namely:

(A) exposing to said body fluid in the internal hollow space of an intra-luminal stent, an implant suspended in said internal hollow space, wherein said implant comprises a surface layer including at least one moiety which specifically binds to and thus immobilizes said at least one known target, and wherein said implant comprises a biologically compatible substrate, to which said at least one moiety is bound by a ligand in said surface layer; and

, after a predetermined time interval,

either (B) removing from said mammalian body said implant either with or without said intra-luminal stent, said implant including said at least one target which is bound to said at least one moiety, and in an optional further step, destroying ex-vivo said at least one target bound to said at least one moiety;

or (C) destroying in situ said at least one target bound to said at least one moiety.

18. Method according to claim 17, wherein said moiety is selected from proteins, polypeptide or fragments thereof, antibodies or fragments thereof, carbohydrates (including polysaccharides), hormones, antioxidants, glycoproteins, lipoproteins, lipids, fat soluble vitamins, bile acids, reactive dyes, allantoin, uric acid, polymyxin, nucleic acid molecules (DNA, RNA, single stranded, double stranded, triple stranded or combinations thereof), or combinations thereof.

19. Method according to claim 17, wherein said moiety is selected from monoclonal antibodies, polyclonal antibodies, synthetic antibodies, antigenic affinity synthetic fragments, antibody fragments retaining their antigenic affinity, Fv antibody fragments, radio labelled antibodies and biotinylated antibodies.

20. Method according to claim 17, which is further characterized by at least one of the following features:

(a) said at least one target is selected from entities comprising antigens and antigenic determinants, and said at least one moiety is selected from monoclonal antibodies which are specific for said at least one target;

(b) said implant is connectable to a catheter;

(c) said implant includes, and is adapted for slow release of, at least one pharmacologically active compound selected from the group consisting of antibacterial drugs, anti-fungal drugs, anti-neoplastic drugs, anti-thrombotic drugs, anti-toxin drugs and antiviral drugs;

(d) said body fluid is blood;

(e) said at least one target is selected from a population of cells and cell fragments, which is at least in part cancerous or pathogenically infected;

(f) said optional further step and said step (C) are carried out by locally applying to said at least one target which is bound to said at least one moiety, at least one of the following, namely, radiation, heat (hyperthermia), sonication, immunotherapy, radioimmunotherapy, genetic therapy or controlled drug release;

(g) the specific monoclonal antibodies in the surface layer are renewed and(or) supplemented by direct administration to the mammalian body of monoclonal antibodies adapted for specific binding to the implant as well as to said target.

21. Method according to claim 20, which is further characterized by at least one of the following features:

(i) said substrate is selected from natural and synthetic polymers, ceramics, glass, metals, metal oxides and fabrics;

(ii) said at least one target is selected from cancer-affected cells such as mature B-cells and T-cells.

(iii) said directly administered monoclonal antibodies comprise a bound ligand.

22. Method according to claim 21, which is further characterized by at least one of the following features:

said ligand comprises at least one substance selected from avidin, biotin, streptavidin, and their analogues;

said monoclonal antibodies bind specifically to B- or T-cell antigenic determinants.

25-27. -27. (canceled)